Skba Capital Management LLC Increases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Skba Capital Management LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 601,330 shares of the company’s stock after buying an additional 36,070 shares during the quarter. Kenvue accounts for 2.0% of Skba Capital Management LLC’s investment portfolio, making the stock its 14th largest holding. Skba Capital Management LLC’s holdings in Kenvue were worth $12,838,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Alerus Financial NA grew its stake in shares of Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC grew its position in Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after purchasing an additional 500 shares in the last quarter. Principle Wealth Partners LLC grew its position in Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after purchasing an additional 500 shares in the last quarter. White Pine Capital LLC increased its stake in Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after buying an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its position in shares of Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after buying an additional 568 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE opened at $23.74 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.36 billion, a P/E ratio of 44.78, a PEG ratio of 2.62 and a beta of 1.25. The stock has a 50-day moving average price of $22.32 and a 200-day moving average price of $22.45. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

Analyst Ratings Changes

KVUE has been the subject of several recent analyst reports. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Barclays boosted their price target on shares of Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Thursday. Piper Sandler lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.